The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.
about
Systemic pharmacological treatments for chronic plaque psoriasisMethotrexate for psoriasisBeta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skinAssessment of anti-cyclic citrullinated peptide in psoriatic arthritis.High prevalence of skin diseases and need for treatment in a middle-aged population. A Northern Finland Birth Cohort 1966 studyThe association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 loci.Serum fatty acid profile in psoriasis and its comorbidity.Potential role of ustekinumab in the treatment of chronic plaque psoriasisPsoriasis and the risk of pneumonia: a population-based study.Interleukin 6 and 8 levels in plasma and fibroblast cultures in psoriasis.Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity.Development of TAP, a non-invasive test for qualitative and quantitative measurements of biomarkers from the skin surfaceSubjective stress reactivity in psoriasis - a cross sectional study of associated psychological traitsUstekinumab biotherapy and real-time psoriasis capacitance mapping: a pilot study.Assessing Cutaneous Psoriasis Activity Using FDG-PET: Nonattenuation Corrected Versus Attenuation Corrected PET Images.Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasisEpidemiology of psoriasis. Review and the German perspective.Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.Quality of life and severity of skin changes in the dynamics of psoriasis.Psychopathological Variables and Sleep Quality in Psoriatic PatientsThe health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people.Increase in circulating sphingosine-1-phosphate and decrease in ceramide levels in psoriatic patients.Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference.Apolipoprotein E gene polymorphism and serum lipid profile in Saudi patients with psoriasis.Methylenetetrahydrofolate reductase (MTHFR) 677C>T gene polymorphism as a possible factor for reducing clinical severity of psoriasis.Hope as a Psychological Factor Affecting Quality of Life in Patients With Psoriasis.Profile of Tumour Necrosis Factor Alpha -308 G/A Gene Polymorphism in Psoriatic Patients in Karnataka, India.Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement.Biological treatments for moderate-to-severe psoriasis: indirect comparison.Secukinumab (AIN-457) for the treatment of Psoriasis.Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology.Analysis of patients' willingness to be mobile, taking into account individual characteristics and two exemplary indications.Enhanced liver fibrosis test in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis: a cross-sectional comparison with procollagen-3 N-terminal peptide (P3NP).Red blood cell distribution width is increased in patients with psoriasis vulgaris: A retrospective study on 261 patients.No association of psoriasis with autoimmune thyroiditis.Tele-assessment of Psoriasis Area and Severity Index: a study of the accuracy of digital image capture.Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.Correlation between Dermatology Life Quality Index (DLQI) scores and Work Limitations Questionnaire (WLQ) allows the calculation of percent work productivity loss in patients with psoriasis.Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static PhyDoes the choice of tariff matter?: A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China.
P2860
Q24188334-BD96DD43-7C2F-4EE6-9DB9-26DD8CA52CA0Q24198123-A98B112C-7C50-4D27-9550-CD5CDA6E15B6Q33415491-C6D8C239-D142-4AD4-BB99-EB2AEE052001Q33419722-46E000E1-DB64-4769-AC06-12503AB7FD04Q33728094-A3F5D06F-D879-44F1-BB91-F954135ECBF7Q33803222-308F4BA9-8CF0-4A4B-894B-53084E78F70FQ33840850-C9FB0545-4440-4421-B65E-89980C5788F0Q33892602-CC2BEA55-713A-4A37-910A-571226774D8EQ34777002-F743F814-AAB1-4AA6-B814-75D0B13D0B8AQ35039946-5BFBF690-118F-46AE-B360-46E5F00C18DAQ35155926-FF182461-561C-4CF3-A7B6-62617D516D81Q35185468-0DB7B420-313B-4293-9B0D-20AA2B11A5DFQ35579958-980BFF72-0F38-4F9C-8A26-472293E5602CQ35878423-6C45715F-B747-4F02-9A55-9AA512F9814FQ36108233-DD881D39-4D5B-4052-960B-A9A32B5CE6F8Q36299430-F89FD4C7-BA8D-438E-B4FE-6637D9ED1808Q36481432-C9A3759F-A280-4EF8-AE30-0428D020F246Q36514683-FA0E43BE-7071-43DF-877B-02D28BAE59F9Q36946153-3D4B4BD5-0771-4003-A3BB-FC68438C0BFBQ37134741-6B4AD623-1ECB-44E8-9398-FB28BE57E1ADQ37172521-09EC50B3-E677-47F9-8F00-8507114419D1Q37642111-D861A7BB-6EF5-447B-B5C4-B9AD993E6000Q37690746-39308C7A-8F8C-44E0-936C-DB003A22084EQ37693885-C35FC4B0-5468-4964-B8A1-8EE80E3FC600Q37711475-8818497F-FA33-48EE-B66D-7B35C9EE3595Q37724932-2EC29D7F-481A-4F36-8687-1BAB98F52C4EQ37734084-DEA2880B-5C52-4478-B31B-F56E52927455Q37961072-EDCF1CBD-B196-4A69-B0AF-1CA4E5C2DA20Q38084746-42FD178E-1A8F-4EA8-AC33-581F7C1F9560Q38662868-5E4C0293-F63C-4C6A-9E7E-0A6097F55A99Q38712213-BA26415E-75F3-4FB0-A31C-23E182A433EDQ38897424-1E31FF22-FB41-4C32-81EE-6825AB374759Q39124718-9FA654F1-C214-449A-9FF4-020C316813DBQ39136407-1B5A5945-2006-450C-8C1F-D5B3A72B680BQ39669246-136F24B2-77A6-49BF-8CED-A68F072D20FFQ40006527-82DAE351-FB60-42FA-9EC7-CC6E14CED13DQ40283992-21D3467F-5EEE-4321-9F27-AD46EB17A94BQ40977555-7169CBBC-D225-49B3-931A-20208153FF00Q41008261-D1B5B3FF-C4DC-4EA5-A4EA-5C250FCEF0A7Q41523826-A996840F-0B93-4D6A-8386-8D4615D040F8
P2860
The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The psoriasis area and severit ...... chronic plaque-type psoriasis.
@ast
The psoriasis area and severit ...... chronic plaque-type psoriasis.
@en
type
label
The psoriasis area and severit ...... chronic plaque-type psoriasis.
@ast
The psoriasis area and severit ...... chronic plaque-type psoriasis.
@en
prefLabel
The psoriasis area and severit ...... chronic plaque-type psoriasis.
@ast
The psoriasis area and severit ...... chronic plaque-type psoriasis.
@en
P2860
P356
P1433
P1476
The psoriasis area and severit ...... chronic plaque-type psoriasis.
@en
P2093
Gottfried Wozel
Jochen Schmitt
P2860
P304
P356
10.1159/000083509
P577
2005-01-01T00:00:00Z